Close Menu

NEW YORK – In vitro diagnostics company Todos Medical announced today it has expanded its partnership with Orot[+] to launch and distribute Todos' early breast cancer detection blood tests, TM-B1 and TM-B2, in Japan.

The firms have entered into a nonbinding memorandum of understanding under which Orot will spend at least $2.5 million on regulatory approval, clinical development, and the commercial launch of the tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.